Depression in primary care: interpersonal counseling vs selective serotonin reuptake inhibitors. The DEPICS Study. A multicenter randomized controlled trial. Rationale and design. by Menchetti, M et al.
STUDY PROTOCOL Open Access
Depression in Primary care: Interpersonal
Counseling vs Selective serotonin reuptake
inhibitors. The DEPICS Study. A multicenter
randomized controlled trial. Rationale and design
Marco Menchetti1*, Biancamaria Bortolotti1, Paola Rucci2,3, Paolo Scocco4,5, Annarosa Bombi1, Domenico Berardi1,
DEPICS Study Group
Abstract
Background: Depression is a frequently observed and disabling condition in primary care, mainly treated by
Primary Care Physicians with antidepressant drugs. Psychological interventions are recommended as first-line
treatment by the most authoritative international guidelines but few evidences are available on their efficacy and
effectiveness for mild depression.
Methods/Design: This multi-center randomized controlled trial was conducted in 9 Italian centres with the aim to
compare the efficacy of Inter-Personal Counseling, a brief structured psychological intervention, to that of Selective
Serotonin Reuptake Inhibitors. Patients with depressive symptoms referred by Primary Care Physicians to psychiatric
consultation-liaison services were eligible for the study if they met the DSM-IV criteria for major depression, had a
score ≥13 on the 21-item Hamilton Depression Rating Scale, and were at their first or second depressive episode.
The primary outcome was remission of depressive symptoms at 2-months, defined as a HDRS score ≤ 7. Secondary
outcome measures were improvement in global functioning and recurrence of depressive symptoms at 12-months.
Patients who did not respond to Inter-Personal Counseling or Selective Serotonin Reuptake Inhibitors at 2-months
received augmentation with the other treatment.
Discussion: This trial addresses some of the shortcomings of existing trials targeting major depression in primary
care by evaluating the comparative efficacy of a brief psychological intervention that could be easily disseminated,
by including a sample of patients with mild/moderate depression and by using different outcome measures.
Trial registration: Australian New Zealand Clinical Trials Registry ACTRN12608000479303
Background
Major Depression (MD) is an important public health pro-
blem, associated with high levels of disability, impairment
in quality of life, and increased mortality rates [1,2], simi-
larly to severe medical conditions like congestive heart fail-
ure and diabetes [3]. Moreover, depression is associated
with high health services utilization, work absenteeism,
and decreased performances at work [4,5] with elevated
direct and indirect social costs. Epidemiological studies
showed that MD has a high prevalence in primary care
ranging from 2.6% to 29.5% [6-8].
Many patients with depression seek help in primary
care and an increasing proportion has been treated in
this setting, especially since the availability of safe and
easy to use antidepressants (ADs) [9]. However, some
problems remain in the management of depression in
primary care, including the insufficient duration of anti-
depressant treatment and the limited use of non-phar-
macological options [10-12]. In particular, psychological
interventions are rarely used even for those patients
who could benefit from them: patients suffering from
mild depression related to stressful life events and
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patients in which the risk/benefits ratio of antidepres-
sants is less favourable (e.g. elderly, frail patients,
patients with polypharmacotherapy, women with post-
partum depression). Several reasons account for this
limited use: the small number of trained therapists in
primary care [13,14], the physician’s positive opinion
and attitude on drug treatment [15,16], the few evidence
on the comparative efficacy and effectiveness of brief
psychotherapies vs antidepressants.
However, psychological interventions are often pre-
ferred by primary care patients [17,18] and are recom-
mended as first-line treatment by the most authoritative
international guidelines [19,20].The APA guidelines [19]
stated that antidepressants or an effective psychotherapy
alone may be considered as the first-line treatment for
patients with mild to moderate major depression. The
National Institute for Clinical Evidence (NICE) guide-
lines [20] recommend not to use antidepressants routi-
nely to treat mild depression because the risk-benefit
ratio is poor and suggest as an alternative a range of
low-intensity psychosocial interventions.
These recommendations are based on few trials
directly comparing antidepressant drugs with different
kinds of psychological interventions in primary care
[21-28]. Therefore the NICE guidelines underscore that
adequately powered Randomized Controlled Trial (RCT)
are warranted with representative participant samples,
reporting relevant outcomes to assess the efficacy of
psychological interventions and antidepressants [20].
The objectives of the RCT described in this paper are:
1) to evaluate the efficacy of a psychological interven-
tion, the Inter-Personal Counseling (IPC), compared
with Selective Serotonin Reuptake Inhibitors (SSRIs), for
mild to moderate MD; 2) and to assess the efficacy of
treatment augmentation with SSRI or IPC in patients
who do not respond to monotherapy.
Methods/Design
Study procedures
Study design
This multi-center randomized controlled trial was con-
ducted in nine academic centres located in Northern,
Central and Southern Italy: Bologna (coordinating cen-
tre), Bari, Cagliari, Foggia, Modena, Pavia, Perugia, Tor-
ino, Varese. The recruitment phase started on May 1st
2006 and finished on May 1st 2008. Each centre set up
a specific collaborative programme with primary care
physicians working in its area, with the aim to improve
the management of depression. In some research units a
collaborative programme was already in place at study
inception, in others it was implemented on the occasion
of the research. Primary Care Physicians (PCPs) were
informed about the DEPICS study protocol during spe-
cific meetings and informal contacts; further, written
materials about eligibility criteria and treatment algo-
rithm were delivered.
Patients were recruited from university-based psychia-
tric consultation-liaison services specifically dedicated to
PCPs. PCPs were encouraged to refer patients recog-
nized as suffering from depressive symptoms; patients
were seen by a consultant psychiatrist and evaluated for
the possible inclusion in the study.
Study protocol approval and trial registration
Participation in the study was voluntary and written
informed consent was obtained. Patients were informed
that they could withdraw their consent to participate at
any time, with no negative consequences on their future
medical treatment. Patients who wished to withdraw
from the study received care as usual. The study proto-
col was approved by the Ethical Committee of Azienda
Ospedaliera Universitaria di Bologna. Eligible patients
received an explanation of the study procedures and
were asked to sign an informed consent. Written docu-
mentation about study methodology and procedures and
a letter for PCP were delivered to all recruited patients.
The PCPs were also periodically informed by letter or
by phone about the course of illness of their patients
during the study.
The trial was registered in the Australian New Zeal-
and Clinical Trials Registry (ANZCTR) as ACTRN
12608000479303.
Inclusion and exclusion criteria
Adult patients suffering from depressive symptoms and
referred from their PCP were potential candidates for
the trial. Patients aged 18 years or older were eligible if
they met criteria for a MD Episode, had a score ≥13 on
Hamilton Depression Rating Scale (HDRS, 21-item ver-
sion) [29], and were at their first or second MD Episode
treated with antidepressants or psychotherapy. Patients
who met all inclusion/exclusion criteria but had a
HDRS score < 13 were reassessed after 1 month (watch-
ful waiting arm); if their HDRS score was ≥13 after 1
month they were enrolled and randomised to IPC or
SSRI. Inclusion and exclusion criteria are shown in
Table 1.
We chose to exclude patients with two or more pre-
vious depressive episodes treated with antidepressants
or psychotherapy, with Borderline or Antisocial Person-
ality Disorder because of the different pattern of
response to treatment and the less favourable prognosis
[30,31].
After a baseline assessment, eligible patients were ran-
domly allocated to a brief structured psychological inter-
vention, IPC, or to antidepressant treatment with SSRI,
the most used class of drugs in primary care.
Randomization and treatment allocation
Randomization sequences, derived from a computer
random number generator, were delivered to each
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centre by the coordinating centre. In each centre,
allocation to treatment group was made by dedicated
research personnel outside the consultation-liaison
service where patients were recruited, assessed and
treated. After baseline assessment and after consent to
participation in the study was obtained, the researcher
was contacted via telephone by clinicians and disclosed
the assignment.
Blinding
Raters who administered assessment’s instruments were
different from the clinicians who provided psychiatric
consultation to PCPs and delivered pharmacological or
psychological interventions. Efforts were made to keep
raters blind to randomization assignment.
Outcomes
The primary outcome was the remission of depressive
symptoms at the 2-month follow up visit, defined as a
HDRS score of 7 or less. Secondary outcome measures
were: improvement in global functioning and recurrence
of depressive symptoms at the 12-months follow up
visit. Patients with a HDRS score ≥ 13 at 2-month fol-
low-up received augmentation with other treatment
(Figure 1).
Intervention
Interpersonal Counseling (IPC)
IPC is a brief manualized psychological intervention,
derived from Interpersonal Psychotherapy (IPT) and sui-
table for different medical contexts. This intervention
can be delivered by trained mental health professionals,
nurses and social workers [32-35]. IPC has been adapted
and tested on patients with several conditions, in asso-
ciation with pharmacological treatment or alone. These
conditions include subthreshold depression [36], major
depression [37], depressive symptomatology after mis-
carriage [38], psychological symptoms after a major phy-
sical trauma [39], stress and distress without serious
medical or psychiatric conditions [32], breast cancer
[40], and distress after myocardial infarction [41].
IPC is focused on patients’ current psychological pro-
blems and social functioning and specifically on four
interpersonal problem areas: prolonged grief, interperso-
nal disputes, role transitions and interpersonal deficits.
Patients are helped to identify effective strategies in
order to deal with their interpersonal problems. In the
original manual [33], IPC consisted of six thirty-minute
sessions, with the initial session being longer (1 hour),
and was self-dosing: the patient determined the number
of sessions and many patients were satisfied with fewer
than six sessions. In our study IPC has been adapted to
accommodate patients’ needs. The recommended num-
ber of therapy sessions was six thirty-minute weekly ses-
sions. Therapists determined if one or two additional
sessions were needed (6+1 or 6+2). IPC sessions were
videotaped if patients provided a written informed
consent.
Training of IPC therapists IPC was delivered by 18
therapists (Bologna 3, Modena 2, Torino 3, Pavia 2, Var-
ese 2, Perugia 1, Foggia 3, Bari 1, Cagliari 1). Therapists
were residents in psychiatry or in clinical psychology
with a clinical experience of at least 2 years. They
attended a 3-day teaching seminar on interpersonal the-
ory’s foundations and IPC structure and techniques con-
ducted by one of the authors (PS), who had previously
trained and supervised the Italian IP-therapists of a
cross-national RCT [42,43]. Before starting the formal
training, trainees were asked to read the Italian transla-
tion of the IPT manual [44] and the IPC treatment
manual by Weissman [30]. During the teaching semi-
nars, videotapes of psychotherapy sessions were pre-
sented and discussed, before simulating an IPC session
with a role-playing. The candidates were encouraged to
use the interpersonal approach when treating their
patients (out of the trial).
Table 1 Study recruitment: inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Age ≥18 years Current moderate to high suicide risk
DSM-IV Major Depressive Episode (MDE) Current/past episodes of mania or hypomania
HDRS score ≥13 Current/past psychotic symptoms
First or second lifetime treated MDE° Borderline personality disorders
Availability to sign informed consent Anti-social personality disorders
Substance abuse or dependence
Cognitive impairment
Effective ongoing antidepressant treatment*
Effective ongoing psychotherapy
Poor knowledge of Italian language
Pregnancy or breastfeeding
° Only previous episodes treated with specific therapeutic options (antidepressants, psychotherapy) were considered.
* Including antidepressants, mood stabilizers, and antipsychotics; only use of moderate dose of sedatives-hypnotics was allowed (doses ≤ 7.5 mg lorazepam
equivalent/day).
Menchetti et al. BMC Psychiatry 2010, 10:97
http://www.biomedcentral.com/1471-244X/10/97
Page 3 of 9
IPC group supervision Subsequently, monthly group
supervisions were scheduled with one of the authors
(PS) in order to discuss cases, to ensure the interven-
tion’s consistency. At each meeting the trainees reported
the problems and challenges they experienced with IPC.
Trainees were requested to present four or five IPC
videotaped sessions to review during group supervision,
choosing the more challenging sessions. These video-
tapes provided indications on the communication style,
techniques and strategies applied by therapists. In this
way, during the supervision meeting, trainees could
learn from the supervisor, but also vicariously from one
PCP Office
Consultant Psychiatrist’s visit:
eligible patients are invited to 
participate in the study.
Informed consent procedure and 
baseline assessment are carried out 
by research staff.
Randomization
IPC
2 months follow-up visit
Non 
Response
6 and 12 
months 
follow-up
6 and 12 
months 
follow-up
4, 6 and 
12 months
follow-up
4, 6 and 
12 months
follow-up
Full or Partial 
Response
SSRI
Full or Partial 
Response
Non 
Response
Patients identified by PCPs as 
depressed are  referred to 
Consultation Liaison Service.
Consultation Liaison 
Service
SSRI
+
IPC
IPC
+
SSRI
Figure 1 Contains study design.
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another (peer-supervision). Working with a group of
trainees means that each could be learning even while
one is the particular focus of the supervisor attention.
The supervisor stimulated trainees to use a peer-
supervision method with all the participants actively
involved in the case discussion with suggestions or com-
ments. As Hillerbrand [45] pointed out, group members
are often able to give feedback to one another that is
more understandable than what the supervisor offers.
Then, peer-supervision was used in any unit between
the monthly-group supervisions.
Antidepressant treatment
Because our aim was to assess the antidepressant treat-
ment for depression as delivered routinely in clinical
practice, we chose two antidepressants, sertraline and
citalopram, among the available SSRIs. These agents have
minimal or modest effects on the cytochrome P-450 iso-
enzyme system which makes them safe even in patients
with physical illnesses and taking other medications.
Moreover, sertraline and citalopram had the lowest cost
among SSRI antidepressants in Italy at study start.
Citalopram was started at 10-20 mg and titrated if
needed to 60 mg and sertraline was started at 25-50 mg
and titrated up to 200 mg. The pharmacological treat-
ment was continued for at least 4-6 months after the
patient had responded as suggested by international
guidelines [19,20]. The psychiatrist was free to choose
between the two pharmacological options according to
his/her personal preference and informed the PCP by
letter about the suggested pharmacological treatment.
Moreover he/she provided psycho-education about anti-
depressants and their side effects. Two or three subse-
quent visits with the consultant psychiatrist were
planned every 2-3 weeks, lasting around 15 minutes in
order to evaluate patients’ compliance, clinical response
and side effects; a specific form was used to assess
adverse events. The only treatment modification allowed
was the switch from sertraline to citalopram and vice
versa.
There were no limitations on the number of PCP’s
visits. Concurrent use of sedatives-hypnotics was
allowed up to a dose < 7.5 mg lorazepam equivalent/day
in both treatment arms. During the study, other psycho-
tropic medications were forbidden; if needed, the patient
was terminated from the protocol and referred to his or
her PCP for alternative treatments.
Combined treatment
Patients with a HDRS score ≥13 at 2-months follow-up
received augmentation with other treatment. In particu-
lar those in the SSRI arm began a regular 6-sessions
IPC; those in IPC arm began the antidepressant therapy
and continued IPC for further 4-6 sessions.
Assessments
At baseline, patients filled out socio-demographic and
clinical forms, including information about medical his-
tory, current pharmacological treatments and health ser-
vices utilization in the last 6 months (including
information about use of both general health and spe-
cialist care and about laboratory tests, instrumental pro-
cedures, admission to hospital). Follow-up visits were
scheduled at 2, 4, 6 months and 1 year; the 4-month
assessment was scheduled only for non-responders who
started the combined treatment at 2 months. Table 2
summarizes instruments administered at each visits.
The assessment was conducted by interviewers not
involved in patients treatment and trained to the use of
instruments and scales. Research personnel was trained
to the use of study instruments in 2 investigator’s meet-
ings, in which videotaped interviews were presented and
rated. In particular, a structured interview guide for the
HDRS was employed in order to facilitate the achieve-
ment of good inter-rater reliability [46]. Certification in
the use of the HDRS was obtained when the total score
did not differ by more than 4 points with the gold stan-
dard (MM) on 3 videotaped cases.
Diagnostic assessment
The diagnostic assessment was carried out at baseline
using the Mini International Neuropsychiatry Interview
(MINI) Plus [47], an instrument that allows to make a
diagnosis according to DSM-IV or International Classifi-
cation of Diseases (ICD-10) criteria. The reliability, sen-
sitivity, and specificity of the MINI are equivalent to
those of the Composite International Diagnostic Inter-
view (CIDI) [48] and the Structured Clinical Interview
for DSM-IV [47] in a clinical population.
The assessment was completed with the section on
diagnosis of borderline personality disorders of the
SCID-II; we used the self-report scale followed, if neces-
sary, by a semi-structured interview [49].
Depressive symptoms
Severity of depressive symptoms was assessed using the
21-item Hamilton Rating Scale for Depression (HDRS-
21) [29] the most widely used outcome measure in trials
on depression. A HDRS score < = 7 denotes the absence
of depression, from 8 to 17 mild depression, from 18 to
24 moderate depression and a score ≥25 indicates severe
depression [50]. In patients aged 65 years or more
depressive symptom severity was also evaluated using
the Geriatric Depression Scale (GDS) [51].
Functioning
We used the Work and Social Adjustment Scale
(WSAS), a self-report 5-item scale that measures func-
tional impairment attributable to an identified problem
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or disorder. WSAS items investigate ability to work,
home management, social leisure, private leisure, and
relationships. A score from 11 to 20 denotes mild dis-
ability, while a score higher than 20 denotes severe dis-
ability [52].
Quality of life
The World Health Organization Quality Of Life (WHO-
QOL) - BREF is used to assess quality of life [53]. It
consists of 24 items organized into four domains: physi-
cal health, psychological health, social relationships, and
environment. Two additional items measure the overall
perception of quality of life and health. Domain scores
are scaled in a positive direction: higher scores denote
higher quality of life [54].
Interpersonal areas
We used two instruments:
1) Interpersonal Problems Questionnaire (IPQ) is a
brief self-report assessment measure, which queries life
events that are relevant to the four focal interpersonal
problem areas addressed in IPT: unresolved grief, role
transitions, interpersonal role disputes and interpersonal
deficits. [55]. It includes 3 different sections, the first
investigating interpersonal relationships, the second
focused on social life and close relationships and the
last exploring the presence of significant life events
occurred in the past 12 months.
2) The 64-item Inventory of Interpersonal Problems
(IIP-64) is self-report measure of maladaptive relation-
ship behaviour used to identify dysfunctional patterns in
interpersonal interactions. This inventory assesses the
severity of interpersonal problems in 8 domains: domi-
neering or controlling, vindictive or self-centred, cold
and distant, socially inhibited, non-assertive, overly
accommodating, self-sacrificing, and intrusive or needy.
The IIP-64 has been widely used to assess psychother-
apy [56].
Other instruments used in the study
In patients aged 65 years or more, if cognitive impair-
ment was suspected, the Mini Mental State Examination
(MMSE) was administered at baseline [57]; patients with
a score of 27 or less were excluded from the study.
Moreover, we used the Attachment Style Question-
naire (ASQ), a 40-item self-report Likert Scale specifi-
cally designed to assess the type of attachment to
significant other. The ASQ includes five scales: confi-
dence (in self and others), discomfort with closeness,
need for approval, preoccupation with relationships, and
relationship as secondary (to achievement). Each sub-
scale represents a dimension central to adult attachment
and each item is scored on a 6-point scale ranging from
totally agree to totally disagree [58].
Patient’s satisfaction was measured only at the follow
up visits with the General Satisfaction Questionnaire
(GSQ), a self-report 7-item assessment scale that mea-
sures satisfaction with treatment received and with
health services accessibility and acceptability [59].
Data analysis
Data management and study monitoring
Data were recorded by research assistants in a database
developed in MS-ACCESS. The data quality was
checked on a regular basis to ensure that data analysis
could be promptly conducted.
Sample size
The sample size was determined using remission mea-
sured with the HDRS as the primary outcome. Data
from previous RCT on MD showed that the remission
rate with SSRI treatment is 35%[60]. Other studies con-
ducted in primary care reported higher remission rates
Table 2 Assessment instruments at each time point
Instrument Baseline Follow-up visits
2 months 4 months 6 months 12 months
MINI Plus X X
SCID II X
HDRS-21 X X X X X
GDS (only patients aged 65 or more) X X X X X
WSAS X X X X X
WHOQOL BREF X X X X X
IIP-64 X X
IPQ X X X
ASQ X
GSQ X X X
List of abbreviations: ASQ = Attachment Style Questionnaire, GDS = Geriatric Depression Scale, GSQ = General Satisfaction Questionnaire, HDRS = Hamilton
Depression Rating Scale, IPQ = Interpersonal Problem Questionnaire, IIP-64 = 64-item Inventory of Interpersonal Problems, MINI Plus = Mini International
Neuropsychiatry Interview Plus, SCID II = Structured Clinical Interview for DSM-IV Axis II Personality Disorders, WSAS = Work and Social Adjustment Scale,
WHOQOL = World Health Organization Quality Of Life.
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with SSRI, ranging from 52 to 67% [24,61]. Assuming an
intermediate 45% remission rate with SSRI and a clini-
cally significant difference of 15% between the two treat-
ments, a sample size of 274 (137 per arm) was
determined that would result in a power of 80% at 0.05
alpha level. Considering a drop-out rate of about 10% at
the first 2 months follow up, we planned to enrol 300
patients (150 per arm).
Statistical analysis
The statistical analysis plan includes the use of logistic
regression analysis to model the probability of remission
at 2 and 6 months as a function of randomization
assignment. For this analysis, patients dropped out from
the study are considered as non-remitters. The same
model is used to predict the need of combined treat-
ment (coded as yes/no) as a function of patient demo-
graphic and clinical characteristics.
Linear mixed models are used to analyse functional
change and change in quality of life from baseline as a
function of treatment, using the baseline score as a cov-
ariate. Satisfaction with treatment is compared between
the treatment arms using Mann-Whitney test.
Discussion
Many studies have been conducted on the treatment of
depression, but mostly on patients with moderate to
severe forms in the mental health setting. Relatively few
trials have been carried out with patients with mild
depression in primary care. In particular, evidence on the
efficacy of psychological interventions in comparison
with antidepressants is scanty. To our knowledge only
eight RCTs comparing different psychological interven-
tions and antidepressants were conducted in primary
care [21-28]. However, methodological issues limit the
findings of these trials: first,, they had very small sample
sizes, thereby increasing the likelihood of Type II error;
moreover the three older ones used tricyclic antidepres-
sants that are now rarely prescribed [21-23]; finally, two
studies recruited only patients suffering from minor
depression or dysthimia [27,28]. As suggested by several
authors, it is crucial that RCTs on psychological interven-
tions conducted in primary care include representative
participant samples, use multiple outcome measures, test
interventions easy to disseminate and evaluate differences
in treatment response as a function of co-existent psy-
chiatric problems and other medical problems [13,62-64].
Considering the challenges researchers must overcome,
the DEPICS study has some points of strengths:
1) The use of broad eligibility criteria in order to
obtain a representative sample, including patients with
mild depression and depressive disorders comorbid with
anxiety disorders or physical illnesses, very common in
primary care setting.
2) The use of different outcome measures and a broad
assessment including severity of depressive symptom,
functioning, quality of life, interpersonal relationships,
and patient’s satisfaction,
3) The evaluation of the efficacy of a brief structured
psychological intervention (IPC) as a monotherapy for
MD in primary care.
Among evidence-based psychotherapies for depression,
the interpersonal approach is one of the most supported,
but qualified psychotherapists are often not available in
primary care. If we want to see widespread implementa-
tion of effective practices such as evidence -based psy-
chotherapies, we need to develop and test “simpler”
versions of evidence based psychosocial treatment that
could be provided by different health-care professionals
who do not necessarily have mental health training [64].
With a view of moving from research evidence to practice,
IPC lends itself to be disseminated in primary care,
because it is a briefer version of evidence-based psychoso-
cial treatments and could be provided by clinicians with
less mental health expertise than IPT or CBT therapists.
The efficacy of IPC has been previously tested in patients
with depressive symptoms related to current stress (mainly
physical illnesses) and subthreshold depression or in indi-
vidual, group and telephone format [32,37-41,65]. One
study evaluated the efficacy of IPC plus venlafaxine for
MD in primary care [36]. Moreover, Bolton et al [65]
tested the efficacy of group IPC in alleviating depressive
symptoms and dysfunction in patients with sub-threshold
or major depression in Uganda. However, IPC was not
previously tested as an individual intervention in mono-
therapy for patients with MD in primary care.
An important limitation of this study is the absence of
a placebo group, usually characterized by a high rate of
spontaneous remission (27% to 43%) [22,66,67]. How-
ever, the present study is part of a more comprehensive
collaborative programme between primary care and men-
tal health services and we chose to employ only an active
comparator in the protocol to match the real-world clini-
cal setting as closely as possible. Another limitation is the
exclusion of patients with more than one clinically signif-
icant depressive episode in their personal history. We
chose to exclude these patients because of the different
pattern of response to treatment and the less favourable
prognosis [9]. Our results therefore cannot be generalized
to patients with chronic or recurrent MD.
In conclusion, the present trial aims to provide evi-
dence on the efficacy of a brief and easy to implement
psychological intervention compared to the most fre-
quently used drug treatments for major depression.
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